Compare State Street SPDR S&P Biotech ETF (XBI) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Zillow Group Inc Class A — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while Zillow Group Inc Class A trades at $29.87 (market cap $6.59B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Zillow Group Inc Class A for 86 Days on average.
| XBI | ZG | |
|---|---|---|
Market Cap | $10.11B | $6.59B |
Volume | 12,903,266 | 1,361,381 |
Sector | Broad Market / Factor | Media |
52-Week High | $169.55 | $74.58 |
52-Week Low | $104.99 | $27.70 |
Typical Hold Time | 38 Days | 86 Days |
Enterprise Value | — | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Zillow Group (ZG) trades at $29.90, up 6.9% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growth to $2.58 billion in 2025 and a return to profitability with net income of $23 million. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though cash flow trends remain volatile with negative net cash flow of $312 million in 2025.
The stock presents a compelling turnaround story with improving profitability and strong analyst price targets averaging $48.87, offering significant upside potential. However, investors face risks from the volatile housing market, high P/E ratio of 130, and ongoing competitive pressures in the real estate technology sector that could challenge future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
